Hemab Therapeutics Holdings, Inc. (COAG)
Data as of , from SEC Form 4 filings.
See up to 3 months of COAG. The 7-day demo opens the 1M and 3M ranges and puts COAG on your watchlist.
Start 7-day demoLatest COAG insider trades
About Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
- CAMBRIDGE, MA
- 2026
- XNAS
COAG Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 36,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
COAG insider transactions (Form 4)
4010 Form 4 filings on record, the earliest from May 4, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Keli Walbert - Director | Grant or award | Stock Option (Right to Buy) | 36,000 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 6,146 | $24.89 footnote F1 | $153K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 61,523 | $24.98 footnote F4 | $1.54M | |
| ||||||
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 3,802 | $24.97 footnote F1 | $95K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 996 | $24.94 footnote F4 | $25K | |
| ||||||
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 6,387 | $24.90 footnote F1 | $159K | |
| ||||||
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 7,921 | $24.34 footnote F1 | $193K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 1,985 | $24.95 footnote F4 | $50K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 1,483 | $24.98 footnote F5 | $37K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 14,149 | $24.47 footnote F6 | $346K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 25,720 | $25.00 footnote F7 | $643K | |
| ||||||
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 3,607,846 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 1,009,052 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 221,188 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 2,541,250 | $18.00 | $45.74M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 133,750 | $18.00 | $2.41M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 87,143 | $24.59 footnote F6 | $2.14M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 10,268 | $25.00 | $257K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 14,611 | $23.77 footnote F7 | $347K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 53,407 | $24.83 footnote F8 | $1.33M | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series A Preferred Stock | 64,680 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series A Preferred Stock | 27,720 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series B Preferred Stock | 42,341 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series B Preferred Stock | 18,146 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series C Preferred Stock | 56,972 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series C Preferred Stock | 10,054 | - footnote F1 | - | |
| ||||||
| Novo Holdings A/S | Other | Common Stock | 4,180,550 | - footnote F1 | - | |
| Novo Holdings A/S | Other | Series Seed Preferred Stock | 23,343 | $0.00 | - | |
| Novo Holdings A/S | Other | Series A Preferred Stock | 71,866 | $0.00 | - | |
| Novo Holdings A/S | Other | Series B Preferred Stock | 62,121 | $0.00 | - | |
| Novo Holdings A/S | Other | Series C Preferred Stock | 32,695 | $0.00 | - | |
| ||||||
| John Maraganore | Other | Common Stock | 17,974 | - footnote F1 | - | |
| John Maraganore | Other | Common Stock | 17,974 | - footnote F1 | - | |
| John Maraganore | Grant or award | Warrants (Right to Buy) | 107,338 | $0.00 | - | |
| John Maraganore | Other | Series B Preferred Stock | 817 | $0.00 | - | |
| John Maraganore | Other | Series C Preferred Stock | 817 | $0.00 | - | |
| ||||||
 Catherine Madigan - Officer | Grant or award | Warrants (Right to Buy) | 145,134 | $0.00 | - | |
| Catherine Madigan - Officer | Grant or award | Stock Option (Right to Buy) | 49,016 | $0.00 | - | |
| Mads Nikolaj Behrndt-Eriksen - Officer | Grant or award | Stock Option (Right to Buy) | 49,016 | $0.00 | - | |
| Mads Nikolaj Behrndt-Eriksen - Officer | Grant or award | Warrants (Right to Buy) | 195,206 | $0.00 | - | |
Item 5.02
Item 2.02, 9.01
Item 2.02, 9.01
Item 5.02
COAG insider trading FAQ
What is the latest insider trade for COAG?
Hemab Therapeutics Holdings, Inc. (COAG) had 1 insider filing in the last 90 days, with the most recent on 2026-09-25. The full record for COAG runs to 10 Form 4 filings, the earliest from 2026-05-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying COAG stock?
No insider purchases of COAG were filed in the last 90 days. 16 purchases are on record for this company.
How many insiders are selling COAG stock?
No insider sales of COAG were filed in the last 90 days.
Where can I see COAG SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects COAG Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Keli Walbert view on EDGAR
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - Novo Holdings A/S view on EDGAR
- - John Maraganore view on EDGAR
- - Catherine Madigan view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where COAG's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow COAG with a 7-day demo
- COAG on your watchlist
- Every COAG Form 4 filing on record
- Up to 3 months of COAG price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
